

Research Article

Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells

Wenbin Wang^{1,*}, Haihua Pan^{2,*}, Feihua Ren³, Hongxia Chen² and  Ping Ren⁴

¹ Wuhan Sixth Hospital Affiliated to Jiangnan University, Wuhan, Hubei, China; ² School of Pharmacy, Hubei University of Science and Technology, Xianning, Hubei, China; ³ School of Public Health, Guizhou Medical University, Guiyang, Guizhou, China; ⁴ College of Medicine and Health Science, Wuhan Polytechnic University, Wuhan, Hubei, China

Correspondence: Ping Ren (xnyrp27@hbust.edu.cn)



Some tumor cells have a high rate of glutamine uptake and exhibit glutamine addiction. Alanine-serine cysteine-preferring transporter 2 (ASCT2) is a major mediator of glutamine supply in many tumor cells, but the underlying effects and mechanisms of ASCT2 in pancreatic cancer (PC) are largely unknown. Our results show that ASCT2 expression is significantly higher in PC than in normal pancreatic duct cells and pancreas. Utilizing the Kaplan–Meier Plotter database, a high expression of *SLC1A5* mRNA was significantly associated with poor overall survival (OS) in patients with PC. shRNA-mediated inhibition of ASCT2 function *in vitro* can significantly decrease glutamine consumption, α -ketoglutarate (α -KG) production and ATP generation and increase the reactive oxygen species (ROS) level. Moreover, the antioxidant N-acetylcysteine partially attenuated the increase in the ROS levels and reduced ATP generation. These data suggest that ASCT2 mediates glutamine metabolism and maintains redox homeostasis in PC. To further investigate whether ASCT2 is involved in PC cell growth, we blocked ASCT2 activity with the ASCT2 inhibitor L- γ -glutamyl-*p*-nitroanilide (GPNA) and silenced the expression of ASCT2 with specific shRNAs. We found that the growth of PC cells was significantly inhibited. Additionally, knockdown of ASCT2 induced apoptosis through the Akt/mTOR signaling pathway. Furthermore, the loss of ASCT2 in BxPC-3 cell xenografts significantly inhibited tumor growth *in vivo*, and this effect was associated with an increase in cleaved caspase-3 expression and a decrease in Ki67 staining. Taken together, our results show that ASCT2 may be utilized as a putative therapeutic target for PC.

Introduction

Pancreatic cancer (PC) is a common gastrointestinal malignancy, and approximately 90% of PC originates from the ductal epithelium in the exocrine part of the gland [1]. It has become the seventh leading cause of cancer deaths worldwide [2], with 5-year survival hovering at approximately 5–10% and life expectancy at diagnosis of less than 5 months [3]. Surgery is effective in the treatment of early PC; however, only a very small proportion of PC patients (approximately 9–15%) are eligible for surgery [4]. Therefore, patients with advanced PC are limited to chemotherapy [5]. To date, gemcitabine treatment of PC is still the drug of choice, but a large number of patients do not respond to gemcitabine due to intrinsic or acquired chemoresistance [6]. Thus, it is necessary to explore the potential drivers of this cancer in order to discover new therapeutic targets for treating PC.

Abnormal glutamine metabolism is one of the hallmarks of cancer cells. Cancer cells rely on increased glutamine uptake, which provides an unlimited growth advantage [7]. Alanine-serine-cysteine transporter 2 (ASCT2; also known as SLC1A5), which belongs to the amino acid transport system ASC family, is the

*These authors contributed equally to this work.

Received: 25 September 2021

Revised: 02 February 2022

Accepted: 25 February 2022

Accepted Manuscript online:

03 March 2022

Version of Record published:

16 March 2022

Apoptosis assay

Apoptosis was detected using the Annexin V-FITC Apoptosis Kit (Beyotime, China). BxPC-3, AsPC-1 and PANC-1 cells expressing the control vector or ASCT2 shRNA were harvested by combining floating cells in the medium and adherent cells detached by 0.25% trypsin, and the cell pellets were washed once with cold phosphate-buffered saline (PBS). The cells were resuspended in 195 μ L Annexin-binding buffer, and 5 μ L Annexin V-FITC and 10 μ L Propidium Iodide (PI) were added before incubation at room temperature for 15 min in the dark. All cells were analyzed using FACS Calibur (BD Biosciences, U.S.A.).

RNA extraction and real-time qPCR

Total RNA was extracted from cells with TRIzol reagent (Invitrogen) according to the manufacturer's instructions. Reverse transcription was performed using the oligo(dT) primer first-strand cDNA synthesis kit (Fermentas, Thermo Scientific, U.S.A.). The relative level of ASCT2 gene was examined using SYBR green-based real-time qPCR normalized to actin expression and presented as percentages of the control. Gene quantification was performed using the $2^{-\Delta\Delta C_q}$ method [15]. The primers used are shown in Supplementary Table S1.

Western blot analysis

BxPC-3, AsPC-1 and PANC-1 cells expressing the control vector or ASCT2 shRNA were treated with or without 200 nM insulin (Sigma) for 2 h. Then, these cells, H6c7 cells or tumor tissue section specimens of xenograft tumors were lysed in RIPA buffer containing PMSF and phosphotransferase inhibitor (Beyotime, China), and 50 μ g total cellular protein was used for each blot, which was separated on SDS/PAGE gels and transferred to PVDF membranes. The membranes were blocked with 5% nonfat milk for 1 h at room temperature and then incubated with primary antibodies in 4°C overnight. The antibodies used were as follows: ASCT2 (1:1000, cat. no. 8057, Cell Signaling Technology, U.S.A.); Bcl-2 (1:1000, cat. no. 4223, Cell Signaling Technology, U.S.A.); Bax (1:1000, cat. no. 2772, Cell Signaling Technology, U.S.A.); AKT (1:1000, cat. no. 9272, Cell Signaling Technology, U.S.A.) and phosphoserine (Ser⁴⁷³) AKT (1:1000, cat. no. 4060, Cell Signaling Technology, U.S.A.); S6K (1:1000, cat. no. 2708, Cell Signaling Technology, U.S.A.) and phosphoserine (Thr³⁸⁹) S6K (1:1000, cat. no. 9205, Cell Signaling Technology, U.S.A.); the translation regulator 4E-binding protein 1 (4E-BP1) (1:1000, cat. no. 9644, Cell Signaling Technology, U.S.A.) and phosphoserine (Thr^{37/46})-4E-BP1 (1:1000, cat. no. 2855, Cell Signaling Technology, U.S.A.); cleaved-caspase 3 (1:1000, cat. no. 9664, Cell Signaling Technology, U.S.A.); and β -actin (1:1000, cat. no. 8457, Cell Signaling Technology, U.S.A.). After incubation with anti-rabbit IgG, HRP-linked antibody (1:1000, cat. no. 7074, Cell Signaling Technology, U.S.A.) for 1 h at room temperature, the protein bands were detected using an ECL detection system (Pierce Biotechnology, Rockford, IL, U.S.A.). The antibodies used are shown in Supplementary Table S2.

Xenograft tumors

Male BALB/C nude mice (6 weeks, weighing 30–35 g) were purchased from Beijing Huafukang Bioscience CO., Ltd. All animals were housed with pressure-controlled ventilation at 25°C and 40–70% humidity in a 12-h light/dark cycle with food and water available *ad libitum*. Mice were divided randomly into two groups (six mice/group). Approximately 5×10^6 BxPC-3 cells (control or ASCT2 shRNA) diluted in 100 μ L PBS containing 50% Matrigel (BD Biosciences) were injected subcutaneously into the right flank of each nude mouse. The tumor volumes were measured every other day for 21 days, and the tumor tissues were extracted rapidly and weighed at the time of euthanasia by breaking their cervical vertebra performed a 0.2–0.5% carbon monoxide exposure. Anesthesia was not required for the subcutaneous injection.

Immunohistochemistry (IHC)

Tumor tissues were fixed in 10% formalin and embedded in paraffin, cut into 4- μ m-thick sections. The tumor sections were incubated with antibodies against ASCT2, Ki67 (1:100, cat. no. 9027 Cell Signaling Technology, U.S.A.) and cleaved caspase-3 overnight at 4°C. The remaining steps were performed using a DAKO CSA Kit (Carpinteria, Santa Clara, CA, U.S.A.). The IHC results were analyzed and scored based on the intensity of staining and the proportion of stained positive cells in a blinded manner with an integrated camera was used to acquire images from five representative fields of each section ($\times 200$).

Statistical analysis

The data are expressed as the mean \pm SD from at least three independent experiments. A two-tailed Student's *t* test, Mann–Whitney U-test, ANOVA and Bonferroni's corrected *t* test were adopted for the statistical analyses.




Figure 1. ASCT2 is up-regulated in PC

(A) ASCT2 mRNA expression in Pei pancreas from the Oncomine database (normal $n=16$, tumor $n=35$). Mann–Whitney U-test paired t test: $**P<0.01$ versus normal pancreatic duct. (B,C) ASCT2 protein expression in PC cell lines and normal pancreatic duct cells. $**P<0.01$, $*P<0.05$ versus H6c7 cells. (D) ASCT2 mRNA expression among Gleason grades in the TCGA dataset. (Gleason 1, $n=31$; Gleason 2, $n=97$; Gleason 3, $n=50$; Gleason 4, $n=2$. Mann–Whitney U-test: $P=0.0042$ versus Gleason 1). (E,F) The Kaplan–Meier plotter downloaded from the Kaplan–Meier plotter database (PC), the Kaplan–Meier plotter of OS (E), HR = 2.02, $P=0.0094$, log-rank test) and relapse-free survival (F), HR = 4.23, $P=0.013$, log-rank test).

Kaplan–Meier curves were estimated and compared between groups by log-rank test. $P<0.05$ was considered statistically significant.

Results

ASCT2 is up-regulated in PC

To investigate the expression levels of ASCT2, we analyzed the mRNA levels of ASCT2 in PC and normal pancreatic tissues using Oncomine microarray gene expression datasets (www.oncomine.org). The *SLC1A5* mRNA levels were up-regulated in PC tissues compared with normal pancreatic duct tissues according to the Pei pancreas dataset in Oncomine (Figure 1A, $P=0.0034$, Mann–Whitney U-test). The analysis of ASCT2 protein showed that ASCT2 was expressed at different levels in PC cell lines and normal pancreatic duct cells and highly expressed in BxPC-3, PANC-1 and AsPC-1 cells, with lower levels detected in H6c7 cells ($*P<0.05$, $**P<0.01$, Figure 1B,C). *SLC1A5* expression among tumors of different Gleason grades in the The Cancer Genome Atlas (TCGA) dataset was analyzed, and the results showed that *SLC1A5* expression increased as the stage evolved (Figure 1D, $P=0.0042$, Bonferroni’s corrected t test). Additionally, we also used the public cancer database KM plotter to analyze the survival of PC patients with different expressions of *SLC1A5*. As shown in Figure 1E,F, *SLC1A5* predicted as a negative index for PC patients. In specific, PC patients with high *SLC1A5* expression had a shorter overall survival (OS) (Figure 1E, Hazard ratio (HR)= 2.02, $P=0.0094$, log-rank test) or relapse-free survival (Figure 1F, HR = 4.23, $P=0.013$, log-rank test) than patients with low expression. The results above indicated that *SLC1A5* was functional in PC.

ASCT2 knockdown suppresses glutamine metabolism in PC

To examine whether ASCT2-mediated glutamine uptake sustains tricarboxylic acid (TCA) cycle anaplerosis and ATP production, we depleted ASCT2 expression by two specific shRNAs in three PC cell lines first and then measured glutamine consumption, α -KG production (a TCA cycle intermediate) and ATP generation. Our results showed that the knockdown of endogenous ASCT2 was >80% efficient (** $P < 0.01$), as determined by real-time qPCR and the immunoblot analysis (Figure 3A). In addition, we observed that glutamine consumption, α -KG production and ATP generation decreased to different degrees in the ASCT2-depleted PC cells with (GPNA, 2 mM) treatment compared with those with the control treatment (* $P < 0.05$, ** $P < 0.01$) (Figure 2A–F). To further investigate the effect of ASCT2 on redox homeostasis in the cell, we used the fluorescent dye DCFH-DA to measure intracellular ROS production. As shown in Figure 2H, ASCT2 elimination caused a dramatic increase in ROS production compared with that in the control (* $P < 0.05$, ** $P < 0.01$). However, when the three ASCT2-depleted PC cell lines were cultured with NAC for 12 h, the ATP content increased, but ROS production declined significantly (* $P < 0.05$, ** $P < 0.01$) (Figure 2G,H). The results suggest that NAC might significantly reverse the effect of ASCT2 knockdown on ATP generation and oxidative stress.

ASCT2 knockdown inhibits the growth and induces programmed cell death (apoptosis) of PC cells

To directly evaluate ASCT2 function in cell growth, we quantified viable cells cultured in ASCT2-depleted cells using cell number counts. Whereas the control cells proliferated substantially over time, the ASCT2-depleted cells showed a pronounced reduction in growth (* $P < 0.05$, ** $P < 0.01$) (Figure 3B). We also assessed whether the ASCT2 inhibitor GPNA treatment altered PC cell growth. As shown in (Figure 3C), after 7 days of treatment with 2 mM GPNA, cell growth was significantly decreased compared with that in the control in BxPC-3, PANC-1 and AsPC-1 cells (* $P < 0.05$, ** $P < 0.01$). These results suggested that ASCT2 inhibition suppressed the proliferation of PC cells. To examine the effect of ASCT2 knockdown on apoptosis in PC, we further performed a flow cytometry assay to measure the apoptosis ratio in three PC cell lines with ASCT2 knockdown. Compared with the control group, the total apoptosis ratio was significantly increased after ASCT2 knockdown (from 0.93 to 4.72% in BxPC-3 cells, from 2.39 to 10.3% in PANC-1 cells, and from 2.46 to 10.95% in AsPC-1 cells; (Figure 4A), Supplementary Figure S1A) (all * $P < 0.01$). Altogether, these results suggest that ASCT2 might play an important role in the growth and survival of PC cells.

ASCT2 knockdown induces apoptosis via the Akt/mTOR pathway in PC

To determine whether ASCT2 knockdown induced apoptosis we further analyzed the expression levels of the apoptosis-related proteins. As shown in Supplementary Figure S1B, C, cleaved caspase-3 protein expression levels increased $20.3 \pm 0.02\%$, $76.6 \pm 0.03\%$ and $67.4 \pm 0.02\%$ and the ratio of Bax/Bcl-2 was also increased 1.2-, 1.2- and 2.6-fold, respectively, in BxPC-3, PANC-1, and AsPC-1 cells expressing shASCT2, compared with those expressing the nontargeting control shRNA ($n = 3$, ** $P < 0.01$). It is reported that insulin has anti-apoptotic activity through activation of the PI3K/Akt pathway [16]. To further verify whether ASCT2 knockdown induced apoptosis by the Akt/mTOR pathway, we treated ASCT2-knockdown cells with insulin for 2 h. As shown in (Figure 4B,C), insulin increased the expression levels of phosphorylated AKT and mTOR downstream factors, i.e., S6K and 4E-BP1 by approximately 41.8%, 75.9%, 16.7% in BxPC-3 cells, and by approximately 37%, 98.8%, 36.5% in PANC-1 cells, respectively. In addition, insulin decreased the ratio of Bax/Bcl-2 by approximately 62.5% in BxPC-3, by approximately 87% in PANC-1 cells ($n = 3$, * $P < 0.05$, ** $P < 0.01$). However, there is no significant difference between with and without treatment after ASCT2 knockdown ($n = 3$, all $P > 0.05$). These results indicate that ASCT2 knockdown might induce apoptosis in PC cells by affecting the expression of Bcl-2 and Bax and inhibiting the Akt/mTOR signaling pathway.

ASCT2 knockdown attenuates tumor growth in nude mice bearing BxPC-3 xenograft tumors *in vivo*

To assess the ability of ASCT2 ablation to inhibit the tumorigenic capacity of PC, we generated BxPC-3 cells expressing a control or ASCT2-specific shRNA. Then, BxPC-3 cells expressing a control or ASCT2-specific shRNA were subcutaneously injected into the right flank of nude mice. Tumor size was analyzed every other day for 21 days, showing a significant decrease in shASCT2 tumor size compared with their control shRNA counterparts (** $P < 0.01$) (Figure 5A). Mice were euthanized after 21 days, and the tumors were isolated, removed, imaged and weighed. Strikingly, compared with the control shRNA tumors, the shASCT2 tumors showed significant reductions in both size and weight (all ** $P < 0.01$) (Figure 5B,C). Western blots of the xenograft tumors revealed that ASCT2 was decreased in shASCT2 tumors compared with the control tumors, while the apoptosis biomarker cleaved caspase-3 showed




Figure 2. Effect of ASCT2 knockdown or chemical inhibition on cell glutamine metabolism in BxPC-3, PANC-1 and AsPC-1 cells

(A–C) Relative changes in (A) glutamine consumption, (B) α -KG production and (C) intracellular ATP content in BxPC-3, PANC-1 and AsPC-1 cells upon ASCT2 knockdown ($*P < 0.05$, $**P < 0.01$, versus the control group). (D–F) Relative changes in (D) glutamine consumption, (E) α -KG production and (F) intracellular ATP content in BxPC-3, PANC-1 and AsPC-1 cells in the presence of the ASCT2 inhibitor GPNA (2 mM) ($*P < 0.05$, $**P < 0.01$, versus the control group). (G,H) Relative changes in (G) intracellular ATP content, (H) ROS generation for control or shASCT2 in the presence or absence of NAC in BxPC-3, PANC-1 and AsPC-1 cells ($*P < 0.05$, $**P < 0.01$, versus the control group or shASCT2).

elevated levels (all $**P < 0.01$) (Figure 5D,F). IHC analysis revealed that the protein expression levels of ASCT2 and Ki67 were lower in shASCT2 tumors than in control tumors, while the level of cleaved caspase-3 was significantly increased (all $**P < 0.01$) (Figure 5E,G). Consistent with the results obtained *in vitro* (Figure 3), the depletion of ASCT2 expression profoundly inhibited tumor cell proliferation, concomitant with a dramatic increase in cell death *in vivo*. Taken together, our results demonstrate that targeting ASCT2 may be an effective approach to PC therapy.

Discussion

The high-expression levels of SLC1A5 have been reported to be overexpressed in many human cancers [10–13,17,18]. Our results also show that ASCT2 mRNA is significantly overexpressed in PC tissue samples or PC cells compared




Figure 3. Effect of ASCT2 knockdown or chemical inhibition on cell proliferation in PC cells

(A) Depletion of ASCT2 expression by two specific shRNAs in BxPC-3, PANC-1 and AsPC-1 cells. The relative ASCT2 mRNA levels were quantified by real-time qPCR; the data shown are an average of triplicates from a single cDNA. The ASCT2 protein levels were analyzed by Western blotting, and β -actin was used as a loading control. (B) The proliferation of BxPC-3, PANC-1 and AsPC-1 cells over 7 days as measured by serial cell counts after ASCT2 knockdown. (C) The cell growth of BxPC-3, PANC-1 and AsPC-1 cells was examined in the presence of the ASCT2 inhibitor GPNA (2 mM) for 1, 3, 5, and 7 days. The data are shown as an average of triplicates. * $P < 0.05$, ** $P < 0.01$, versus the control group.

with normal pancreatic ductal cells. Considerable evidence support that increased ASCT2 expression is closely related to poor prognosis, such as non-small cell lung cancer [10], colorectal cancer [9], prostate cancer [19] and gastric cancer [20]. Our study also demonstrated that higher expression of ASCT2 in PC was significantly correlated with TNM stages and poor prognosis of these individuals through the Kaplan–Meier plotter analysis. Therefore, ASCT2 could be considered as a promising pathological marker for predicting a worse outcome in PC, which was in accordance with previous literature [14].

The ASCT2 transporter has been recently reported to be responsible for glutamine uptake in PC cells [21], but little is known about how ASCT2 is involved in glutamine metabolism in PC cells. Our results suggest that blocking ASCT2 using either chemical or genetic means (ASCT2 shRNA knockdown) significantly decreased glutamine consumption,




Figure 4. Effect of ASCT2 knockdown on cell apoptosis through the Akt/mTOR signaling pathway

(A) The rate of cell apoptosis was detected through flow cytometry in BxPC-3 and PANC-1 cells upon ASCT2 knockdown. (B,C) BxPC-3 and PANC-1 cells were infected with a control or ASCT2 lentiviral shRNA and then treated with or without 200 nM insulin for 2 h. A Western blotting analysis of the expressions of AKT, p-AKT (Ser⁴⁷³), 4E-BP1, p-4E-BP1, Bcl-2, and Bax proteins. β -actin was used as the loading control. * P <0.05, ** P <0.01, versus the control group.

α -KG production and ATP generation. These results indicate that ASCT2-mediated glutamine uptake sustains TCA cycle anaplerosis and ATP production.

Son et al. reported that glutamine deprivation leads to an increase in ROS in human pancreatic ductal adenocarcinoma (PDAC) cells [22]. Newsholme et al. released research suggesting that glutamine is a precursor of reduced glutathione (GSH) and can also prevent the mitochondria from oxidative damage [23]. Tamoxifen and Raloxifene can block the cellular uptake of glutamine by inhibiting ASCT2, thus reducing the intracellular GSH level and producing certain cytotoxicity. Concurrently, the cytotoxicity of the two drugs can be reversed by increasing GSH through the addition of NAC and 17- β -estradiol treatment [24]. Therefore, we speculate that ASCT2-mediated glutamine uptake could play a major role in maintaining redox balance. To test this hypothesis, we assessed ROS levels and ATP production upon ASCT2 knockdown in the absence or presence of NAC. Indeed, ASCT2 knockdown induces ROS and reduces ATP generation, and NAC partially attenuates the increase in ROS and reduction in ATP generation. Together, these data support the idea that ASCT2 is used by PC cells to regulate glutamine metabolism and maintain redox homeostasis.




Figure 5. ASCT2 knockdown attenuates tumor growth in nude mice bearing BxPC-3 xenograft tumors *in vivo*

(A) The xenograft tumors of BxPC-3 cells (shRNA-Control, $n=6$; shRNA-ASCT2, $n=6$) were measured every 2 days to assess their growth. Two perpendicular diameters of the xenograft tumor were examined and converted into a tumor volume (mm³) using the formula $(a \times b^2)/2$, where 'a' and 'b' refer to the longer and shorter dimensions, respectively. ** $P < 0.01$ versus the control group. (B, C) The tumors were removed and photographed after the mice were anesthetized. The final tumor weights in each group were measured at the end of the experiment. Scale bar, 1 cm. (D, F) The Western blot analysis of the protein expression of ASCT2 and cleaved caspase-3 in tissue sections of xenografts treated with either ASCT2-shRNA or nontargeting shRNA. β-Actin was used as the loading control. (E) Representative staining of ASCT2, Ki67 and cleaved caspase-3 in tumor sections derived from (B). Magnification = 200×. (G) Assessment of ASCT2, Ki67 and cleaved caspase-3 expression using the semiquantitative scoring system. ** $P < 0.01$ versus the control group.

There were many reports showed that ASCT2 performed a significant function in cancer cell proliferation and apoptosis [9,13,25,26]. However, there is no convincing data to implicate ASCT2 involved in the initiation and progression of PC. Our study showed that blockade of ASCT2-mediated glutamine regulation by GPNA or depletion of ASCT2 expression by specific shRNA inhibited the growth of PC cells in culture. In addition, knockdown of ASCT2 induced apoptotic cell death. Furthermore, we elucidated the mechanisms by which ASCT2 knockdown induced cell apoptosis. ASCT2 suppression significantly decreased Bcl-2 expression and increased Bax and cleaved caspase-3 expression. Therefore, the mechanisms of apoptosis were related to the mitochondrial pathway (Bcl-2/Bax).

Furthermore, we confirmed our findings *in vivo* using a model of human PC xenografts in nude mice. We found that knocking down ASCT2 inhibited the relative tumor volume and weight. According to the IHC and Western blotting results, the expression levels of ASCT2 and Ki67 protein were decreased while the cleaved caspase-3 expression

levels were clearly increased in shASCT2 tumors compared with control tumors. These findings reveal that suppressing ASCT2 inhibited the formation of subcutaneous tumor nodules by inhibiting cell proliferation and promoting apoptosis. Combined with the results of the *in vitro* experiment, these data suggest that ASCT2 could be a potential candidate therapeutic target in PC.

It is reported that the mTOR inhibitor, rapamycin decreased ASCT2 mRNA expression in SK-Hep1 cells, that in turn depressed the mTOR signaling by decreasing the p70 S6K1 and eukaryotic initiation factor 4E-BP1 phosphorylation in a reciprocal effect [27]. ASCT2 suppression significantly decreased glutamine uptake, which led to a decrease in the phosphorylation of Akt kinase on Ser⁴⁷³, the 70-kDa ribosomal protein S6 kinase and eukaryotic initiation factor-4E (eIF4E) binding protein-1 (4E-BP1) in prostate cancer [13], breast cancer [28] and hepatocellular carcinoma [27]. However, very recently, Bothwell's group reported the link between ASCT2 expression and mTOR function initially, proposed that target suppression or knockout of ASCT2 is unaffected cellular proliferation and mTORC1 signaling in either liver cancer cell type [29]. What is ASCT2 expression and the mTOR signaling pathway in PC? Our study showed that the phosphorylation of Akt, S6K and 4E-BP1 induced by insulin was notably attenuated after ASCT2 knockdown, which indicate that ASCT2 knockdown induces cell apoptosis through the Akt/mTOR signaling pathway.

In conclusion, we have revealed connections between ASCT2 and the development and progression of PC *in vivo* and *in vitro*. ASCT2 is highly expressed in PC, and the depletion of ASCT2 expression likely inhibits glutamine metabolism, ROS production and PC cell growth and survival. Our results also indicate a potential mechanism for apoptosis caused by ASCT2 knockdown. Therefore, ASCT2 may be a promising target for new drugs to treat PC.

Data Availability

All supporting data are included in supplementary files. Raw data associated with the paper are available and can be accessed by contacting the authors.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

This work was supported by the National Natural Science Foundation of China [grant number 81502635 (to Ping Ren)], Scientific Research start-up fund of the talents of introduction (training) of Wuhan Polytechnic University [grant number 2022RZ001 (to Ping Ren)] and the Health and Family Planning Commission of Hubei Province of China [grant number WJ2019M096 (to Wenbin Wang)].

CRedit Author Contribution

Wenbin Wang: Resources, Supervision, Validation, Methodology. **Haihua Pan:** Resources, Supervision, Validation, Methodology. **Feihua Ren:** Software, Methodology. **Hongxia Chen:** Formal analysis, Validation. **Ping Ren:** Data curation, Funding acquisition, Project administration, Writing—review & editing.

Ethics Approval

All animal experiments took place at the animal laboratory of Hubei University of Science and Technology. In the process of operation, the action is gentle to reduce the shock and injury to animals. After the establishment of the model, the animals were executed to minimize the pain: the mice were killed by dislocation of vertebrae. The animal corpses were packed in black plastic bags and stored at low temperature and treated by the Laboratory Animal Center of Hubei University of Science and Technology. All animal experiments were approved by the Institutional Animal Care and Use Committee of Hubei University of Science and Technology with approval number HBUST-IACUC-2018-01022.

Abbreviations

α -KG, α -ketoglutarate; ASCT2/SLC1A5, alanine-serine-cysteine transporter 2; ATP, adenosine triphosphate; DCFH-DA, dichlorodihydrofluorescein diacetate; DMEM, Dulbecco's modified Eagle's medium; eIF4E, eukaryotic initiation factor-4E; FBS, fetal bovine serum; GPNA, L- γ -glutamyl-p-nitroanilide; GSH, glutathione; HR, Hazard Rate; IHC, Immunohistochemistry; NAC, N-acetyl-L-cysteine; OS, overall survival; PBS, phosphate-buffered saline; PC, Pancreatic cancer; PDAC, pancreatic ductal adenocarcinoma; PI, Propidium Iodide; qRT-PCR, quantitative reverse transcriptase polymerase chain reaction; ROS, reactive oxygen species; TCA, tricarboxylic acid; TCGA, The Cancer Genome Atlas; 4E-BP1, translation regulator 4E binding protein 1.

References

- 1 El-Zahaby, S.A., Elnaggar, Y. and Abdallah, O.Y. (2019) Reviewing two decades of nanomedicine implementations in targeted treatment and diagnosis of pancreatic cancer: an emphasis on state of art. *J. Control. Release* **293**, 21–35, <https://doi.org/10.1016/j.jconrel.2018.11.013>
- 2 Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J. Clin.* **71**, 209–249, <https://doi.org/10.3322/caac.21660>
- 3 The, L.G.H. (2021) Pancreatic cancer: a state of emergency? *Lancet Gastroenterol. Hepatol.* **6**, 81, [https://doi.org/10.1016/S2468-1253\(20\)30397-6](https://doi.org/10.1016/S2468-1253(20)30397-6)
- 4 Patra, C.R., Bhattacharya, R., Wang, E., Katarya, A., Lau, J.S., Dutta, S. et al. (2008) Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. *Cancer Res.* **68**, 1970–1978, <https://doi.org/10.1158/0008-5472.CAN-07-6102>
- 5 Kao, T.-M., Liu, Y.-S., Shen, Y.-S., Chang, H.-J. and Chen, L.-T. (2018) Cure of unresectable, locally advanced pancreatic cancer after multidisciplinary therapy. *J. Cancer Res. Pract.* **5**, 27–31, <https://doi.org/10.1016/j.jcrpr.2017.10.001>
- 6 Coothankandaswamy, V., Cao, S., Xu, Y., Prasad, P.D., Singh, P.K., Reynolds, C.P. et al. (2016) Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer. *Br. J. Pharmacol.* **173**, 3292–3306, <https://doi.org/10.1111/bph.13616>
- 7 Daye, D. and Wellen, K.E. (2012) Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. *Semin. Cell Dev. Biol.* **23**, 362–369, <https://doi.org/10.1016/j.semcdb.2012.02.002>
- 8 Jiang, H., Zhang, N., Tang, T., Feng, F., Sun, H. and Qu, W. (2020) Target the human alanine/serine/cysteine transporter 2 (ASCT2): achievement and future for novel cancer therapy. *Pharmacol. Res.* **158**, 104844, <https://doi.org/10.1016/j.phrs.2020.104844>
- 9 Huang, F., Zhao, Y., Zhao, J., Wu, S., Jiang, Y., Ma, H. et al. (2014) Upregulated SLC1A5 promotes cell growth and survival in colorectal cancer. *Int. J. Clin. Exp. Pathol.* **7**, 6006–6014
- 10 Hassanein, M., Hoeksema, M.D., Shiota, M., Qian, J., Harris, B.K., Chen, H. et al. (2013) SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. *Clin. Cancer Res.* **19**, 560–570, <https://doi.org/10.1158/1078-0432.CCR-12-2334>
- 11 Sun, H.W., Yu, X.J., Wu, W.C., Chen, J., Shi, M., Zheng, L. et al. (2016) GLUT1 and ASCT2 as predictors for prognosis of hepatocellular carcinoma. *PLoS ONE* **11**, e168907, <https://doi.org/10.1371/journal.pone.0168907>
- 12 Wang, Q., Beaumont, K.A., Otte, N.J., Font, J., Bailey, C.G., van Geldermalsen, M. et al. (2014) Targeting glutamine transport to suppress melanoma cell growth. *Int. J. Cancer* **135**, 1060–1071, <https://doi.org/10.1002/ijc.28749>
- 13 Wang, Q., Hardie, R.A., Hoy, A.J., van Geldermalsen, M., Gao, D., Fazli, L. et al. (2015) Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. *J. Pathol.* **236**, 278–289, <https://doi.org/10.1002/path.4518>
- 14 Kaira, K., Sunose, Y., Arakawa, K., Sunaga, N., Shimizu, K., Tominaga, H. et al. (2015) Clinicopathological significance of ASC amino acid transporter-2 expression in pancreatic ductal carcinoma. *Histopathology* **66**, 234–243, <https://doi.org/10.1111/his.12464>
- 15 Livak, K.J. and Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2^{-ΔΔCT} method. *Methods* **25**, 402–408, <https://doi.org/10.1006/meth.2001.1262>
- 16 Rieder, S., Michalski, C.W., Friess, H. and Kleeff, J. (2011) Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer. *Anticancer Agents Med. Chem.* **11**, 427–433, <https://doi.org/10.2174/187152011795677454>
- 17 Nikkuni, O., Kaira, K., Toyoda, M., Shino, M., Sakakura, K., Takahashi, K. et al. (2015) Expression of amino acid transporters (LAT1 and ASCT2) in patients with stage III/IV laryngeal squamous cell carcinoma. *Pathol. Oncol. Res.* **21**, 1175–1181, <https://doi.org/10.1007/s12253-015-9954-3>
- 18 Honjo, H., Kaira, K., Miyazaki, T., Yokobori, T., Kanai, Y., Nagamori, S. et al. (2016) Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma. *J. Surg. Oncol.* **113**, 381–389, <https://doi.org/10.1002/jso.24160>
- 19 Li, R., Younes, M., Frolov, A., Wheeler, T.M., Scardino, P., Ohori, M. et al. (2003) Expression of neutral amino acid transporter ASCT2 in human prostate. *Anticancer Res.* **23**, 3413–3418
- 20 Lu, J., Chen, M., Tao, Z., Gao, S., Li, Y., Cao, Y. et al. (2017) Effects of targeting SLC1A5 on inhibiting gastric cancer growth and tumor development in vitro and in vivo. *Oncotarget* **8**, 76458–76467, <https://doi.org/10.18632/oncotarget.19479>
- 21 Roux, C., Riganti, C., Borgogno, S.F., Curto, R., Curcio, C., Catanzaro, V. et al. (2017) Endogenous glutamine decrease is associated with pancreatic cancer progression. *Oncotarget* **8**, 95361–95376, <https://doi.org/10.18632/oncotarget.20545>
- 22 Son, J., Lyssiotis, C.A., Ying, H., Wang, X., Hua, S., Ligorio, M. et al. (2013) Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. *Nature* **496**, 101–105, <https://doi.org/10.1038/nature12040>
- 23 Newsholme, P., Lima, M.M., Procopio, J., Pithon-Curi, T.C., Doi, S.Q., Bazotte, R.B. et al. (2003) Glutamine and glutamate as vital metabolites. *Braz. J. Med. Biol. Res.* **36**, 153–163, <https://doi.org/10.1590/S0100-879X2003000200002>
- 24 Todorova, V.K., Kaufmann, Y., Luo, S. and Klimberg, V.S. (2011) Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake. *Cancer Chemother. Pharmacol.* **67**, 285–291, <https://doi.org/10.1007/s00280-010-1316-y>
- 25 Ren, P., Yue, M., Xiao, D., Xiu, R., Gan, L., Liu, H. et al. (2015) ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation. *J. Pathol.* **235**, 90–100, <https://doi.org/10.1002/path.4429>
- 26 Ye, J., Huang, Q., Xu, J., Huang, J., Wang, J., Zhong, W. et al. (2018) Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth. *J. Cancer Res. Clin. Oncol.* **144**, 821–833, <https://doi.org/10.1007/s00432-018-2605-9>
- 27 Fuchs, B.C., Finger, R.E., Onan, M.C. and Bode, B.P. (2007) ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells. *Am. J. Physiol. Cell Physiol.* **293**, C55–C63, <https://doi.org/10.1152/ajpcell.00330.2006>
- 28 Geldermalsen, M.V., Wang, Q., Nagarajah, R., Marshall, A.D. and Holst, J. (2016) ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. *Oncogene* **35**, 3201–3208, <https://doi.org/10.1038/nc.2015.381>
- 29 Bothwell, P.J., Kron, C.D., Wittke, E.F., Czerniak, B.N. and Bode, B.P. (2018) Targeted suppression and knockout of ASCT2 or LAT1 in epithelial and mesenchymal human liver cancer cells fail to inhibit growth. *Int. J. Mol. Sci.* **19**, 2093, <https://doi.org/10.3390/ijms19072093>